sciencePipeline Spotlight

The Future of Monthly GLP-1s

Once-weekly was the breakthrough that made GLP-1s mainstream. The next frontier is monthly — and several candidates are already in development.

When semaglutide moved from twice-daily exenatide to once-weekly dosing, adherence and patient experience both improved sharply. The natural next question is: can we go longer? A once-monthly GLP-1 — a single injection every four to six weeks — would change how patients fit treatment into life, especially for travel, work schedules, and long-term maintenance.

None of the monthly GLP-1 candidates currently in development are FDA-approved. Some are in early clinical work, some are in Phase 2, and several aren't yet in trials. Dosing, formulation, side-effect profiles, and even which candidates survive to launch will change before any of these reach pharmacies. This article is a snapshot of where things stood at the time of writing.

For patients tracking what comes next after weekly pens, here is the landscape — and a realistic view of how soon any of it actually arrives.

What it is

A monthly GLP-1 would deliver therapeutic drug levels for roughly four to six weeks per injection, instead of one week. The challenge is not just chemistry; it is sustaining a tolerable, steady drug exposure long enough to last a month without producing intolerable peak side effects or sub-therapeutic troughs.

Several technical approaches are in play. One is depot formulations — a single injection that slowly releases drug over weeks. Another is engineered protein variants with longer intrinsic half-lives. A third is combination approaches that pair a long-acting GLP-1 backbone with another molecule (like bimagrumab, which targets the activin pathway and may help preserve muscle mass during weight loss).

In practical terms, the goal is a once-monthly injection — done at home or in a clinic — that produces weight loss and metabolic improvement comparable to today's weekly drugs, without the daily-life friction of a weekly schedule.

How it compares

Versus weekly GLP-1s, the convenience argument is obvious — one injection per month rather than 52 per year. The clinical argument is less obvious. Today's once-weekly drugs already produce strong adherence in trials, and the gain from going monthly might be more about quality of life than about better outcomes.

Versus longer-acting metabolic drugs in other categories (like the older long-acting insulins), the GLP-1 monthly concept faces a unique constraint: side effects scale with peak drug levels, and a monthly depot would need to avoid the kind of front-loaded peak that drives intolerable nausea after each shot.

Versus combination programs like bimagrumab plus tirzepatide, the picture is different again. Combinations aim to improve the quality of weight loss (preserving more lean mass) more than the cadence of dosing. Some combinations may end up as weekly drugs, not monthly.

The competitive landscape includes Eli Lilly, Novo Nordisk, and several smaller biotechs. The first FDA-approved monthly GLP-1 is unlikely before the late 2020s or early 2030s, depending on Phase 2 data and how trial design evolves.

What to know if you're tracking this

A realistic view of the monthly timeline

hourglass_top

Years away, not months

The closest monthly candidates are in early to mid clinical development. Expect a multi-year wait, with the first approvals more likely late this decade than next year.

experiment

Most candidates won't reach launch

Drug development attrition is high. Several molecules in current pipelines will fail in trials or be deprioritized for commercial reasons. The eventual leader is not necessarily the most-hyped today.

vaccines

Weekly works well for most patients

Once-weekly dosing already produces strong adherence in most trials. A monthly option will be welcome, but going from weekly to monthly is a quality-of-life improvement more than a clinical breakthrough.

Common questions

Common Concerns

When will a monthly GLP-1 be available?expand_more

No monthly GLP-1 is currently FDA-approved. Candidates are in clinical development, but the realistic timeline for the first approval is late this decade or beyond. Specific dates would be speculation until manufacturers file.

Will a monthly GLP-1 work as well as a weekly one?expand_more

That is exactly what trials need to demonstrate. The hope is comparable efficacy with better convenience. The risk is sub-therapeutic troughs or peak-driven side effects. Early trial data will tell.

Is bimagrumab a monthly GLP-1?expand_more

No. Bimagrumab is an activin receptor antagonist — it targets a different pathway. It is being studied in combination with tirzepatide to help preserve lean mass during weight loss. The combination programs are not currently designed as monthly dosing.

Can I get a monthly GLP-1 from a compounding pharmacy?expand_more

No legitimate monthly GLP-1 exists today, so any product sold under that name is unverified and unsafe. Compounding pharmacies cannot create FDA-approved monthly formulations that do not exist commercially.

Keep exploring

Browse all GLP-1 guides.